drugset / Trial / NCT06814938
A Study of a Novel Precision Medicine Approach For Obesity
Phase 4
Active not recruiting
135 enrolled
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNational Institutes of Health (NIH) · collabPhenomix Sciences · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Timeline
- Start
- 2025-02-21
- Primary completion
- 2027-12
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 2.4 mg | Subcutaneous |